SOURCE: Goldman Small Cap Research, Inc.

August 26, 2013 09:32 ET

Structural Changes to Benefit Nuvilex Shareholders

BALTIMORE, MD--(Marketwired - Aug 26, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that the recently announced structural changes by Nuvilex, Inc. (OTCQB: NVLX) should benefit the Company's shareholders.

In order to more effectively operate and streamline leadership's focus, the Company announced last week that it has restructured into three divisions.

The first of these, Nuvilex, Inc., will house the live-cell encapsulation technology and all of its associated licenses; the technology will be used for the development of treatments for cancer and diabetes. The second division, Medical Marijuana Sciences, Inc., will focus on the use of constituents of Cannabis for the development of treatments for brain and pancreatic cancers. This division will also include certain products from the Company's Knock-Out Technologies subsidiary. A third non-biotech division will consist of the Company's nutraceutical formulations and their associated product names.

As exciting as the nutraceutical business may be, management needs to target its resources and energies into the success of its biotechnology divisions. Frankly, the multi-billion dollar opportunities for a firm that owns rights to a potentially blockbuster live-cell encapsulation platform to treat oncology and diabetes is huge, as are its prospects in medical marijuana research and development to treat cancer.

With the prospect of engaging in a development relationship with a larger biotech or pharmaceutical firm which may even lead to a buyout of the Company, pending continued success of its exciting encapsulation delivery system platform, perhaps management should consider making additional structural changes. These could include a divestiture of the nutraceutical business altogether or perhaps executing a spin-off of the medical marijuana business. These prospective moves make sense given the valuations that firms are afforded in the medical marijuana space.

Generally speaking, shareholders typically benefit from ownership in pure-play, single-focused firms, rather than those engaged in multiple business lines as the laser-focused companies are afforded much higher valuations. Moreover, when looking further down the road, M&A is a much easier process in which to engage when the target company has a single, deep line of business, rather than shallow, multiple lines of business. While Nuvilex leadership has not broached this subject in any filings or releases, clearly the sum of the parts of the Company may prove to be even more valuable to shareholders than the current Nuvilex entity, as currently constituted.

To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:

Contact Information